- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
ACADIA Pharmaceuticals Inc(ACAD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ACAD
11/18/2026: ACAD (3-star) is currently NOT-A-BUY. Pass it for now.
ACADIA Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in central nervous system disorders and rare diseases. Its primary business strengths rest on established commercial products, notably NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, which drive steady top-line revenues. The core investment story centers on expanding these flagship franchises into international markets and additional clinical indications. Key risks include revenue concentration, regulatory hurdles, and potential pipeline setbacks. The stock suits growth-oriented investors comfortable with biotech volatility, while market participants should monitor ongoing prescription trends and clinical developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | ACADIA offers solid double-digit top-line expansion driven by the commercial scaling of NUPLAZID and DAYBUE. |
| Momentum investor | Mixed fit | Momentum fit is conditional on positive clinical readouts and breakout price trends amidst biotech sector volatility. |
| Value investor | Mixed fit | The company trades at reasonable valuation multiples relative to commercial revenues, though typical biotech pipeline risks apply. |
| Dividend investor | Weak fit | ACADIA retains earnings to fund clinical trials and commercial growth and does not pay a dividend. |
| Low-risk investor | Weak fit | Biotechnology equities carry inherent clinical trial, regulatory, and price volatility risks unsuitable for low-risk strategies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stock prices frequently experience sharp fluctuations around regulatory decisions and clinical data announcements. |
| Valuation risk | Medium | Valuations depend heavily on the continued commercial uptake and patent protection of core revenue drivers. |
| Competition risk (CNS and rare disease therapeutics) | Medium / high | The company faces continuous competition from alternative therapies and emerging pipeline assets developed by industry peers. |
| Business quality | Medium / high | ACADIA features established commercial products, growing revenues, and validated regulatory expertise. |
| Dividend income | Low / none | The firm distributes no dividend income, focusing entirely on capital appreciation and reinvestment. |
| Execution risk | Medium | Successful commercial execution and pipeline progression remain vital for sustaining long-term financial growth. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.17B USD | Price to earnings Ratio 8.64 | 1Y Target Price 30.32 |
Price to earnings Ratio 8.64 | 1Y Target Price 30.32 | ||
Volume (30-day avg) 2.4M shares | Beta 0.89 | 52 Weeks Range 15.86 - 30.96 | Updated Date 11/18/2026 |
52 Weeks Range 15.86 - 30.96 | Updated Date 11/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.12 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.0%
- Active BUY / eligible
- 67 / 108
- 30-Day BUY Count Change
- +22
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 43.6%
- Active BUY / eligible
- 17 / 39
- 30-Day BUY Count Change
- +10
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 43.23% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Neurological Franchise (NUPLAZID) | Commercial sales of NUPLAZID (pimavanserin) for Parkinson's disease psychosis in the United States. | This serves as the foundational cash-flow engine for the company. |
| Rare Disease Franchise (DAYBUE) | Commercial sales of DAYBUE (trofinetide) for Rett syndrome across approved markets. | This represents the primary growth catalyst and secondary revenue pillar. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When After Market | Estimate 0.19 | Actual 0.31 |
Profitability
Profit Margin 30.13% | Operating Margin (TTM) 10.18% |
Management Effectiveness
Return on Assets (TTM) 4.89% | Return on Equity (TTM) 31.43% |
Valuation
Trailing PE 8.64 | Forward PE 21.05 | Enterprise Value 2.34B | Price to Sales(TTM) 2.63 |
Enterprise Value 2.34B | Price to Sales(TTM) 2.63 | ||
Enterprise Value to Revenue 1.94 | Enterprise Value to EBITDA 17.3 | Shares Outstanding 172.83M | Shares Floating 129.32M |
Shares Outstanding 172.83M | Shares Floating 129.32M | ||
Percent Insiders 0.33 | Percent Institutions 98.04 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

